Gyre Therapeutics, Inc. (GYRE) SEC Filings — 2024

Filings

• Gyre Therapeutics Files 8-K: Material Agreement & Exhibits — 8-K · Nov 27, 2024
• Gyre Therapeutics Files Q3 2024 10-Q — 10-Q · Nov 13, 2024
• Luo Ying Files 13D for Gyre Therapeutics — SC 13D · Sep 6, 2024
• Gyre Therapeutics Files Q2 2024 10-Q — 10-Q · Aug 13, 2024
• Gyre Therapeutics Appoints New CMO, Elects Director — 8-K · Aug 8, 2024
• Gyre Therapeutics Faces Nasdaq Delisting Warning — 8-K · Jul 5, 2024
• Gyre Therapeutics Changes Fiscal Year End — 8-K · Jun 17, 2024
• Gyre Therapeutics Files 8-K with Financials and Exhibits — 8-K · May 30, 2024
• Gyre Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 13, 2024
• Gyre Therapeutics Files 8-K on Operations and Financials — 8-K · May 9, 2024
• Acelyrin to Acquire Gyre Therapeutics for $1/Share + CVR — 8-K · May 8, 2024
• Gyre Therapeutics Announces 2024 Annual Meeting of Stockholders on June 12, 2024 — DEF 14A · Apr 29, 2024
• Gyre Therapeutics, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 27, 2024
• Gyre Therapeutics Faces Nasdaq Delisting Warning — 8-K · Mar 26, 2024
• Gyre Therapeutics Files 8-K on Financials — 8-K · Mar 26, 2024
• Gyre Therapeutics Appoints New CMO and CSO — 8-K · Mar 21, 2024
• Gyre Therapeutics Files 8-K on Financial Condition & Regulation FD — 8-K · Feb 14, 2024
• Gyre Therapeutics, Inc. SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• GNI Group Amends Gyre Therapeutics Stake; Signals Ownership Change — SC 13D/A · Jan 24, 2024
• Gyre Therapeutics Amends 8-K on Delisting Notice, Officer Changes — 8-K/A · Jan 19, 2024
• GYRE Amends 8-K for Oct 30 Asset Acquisition/Disposition — 8-K/A · Jan 12, 2024